Welcome to our dedicated page for Tevogen Bio SEC filings (Ticker: TVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tevogen Bio Holdings Inc. (TVGN) SEC filings page on Stock Titan aggregates the company’s official disclosures from the U.S. Securities and Exchange Commission, offering a structured view into this clinical-stage biotechnology issuer’s regulatory record. As a Nasdaq-listed company, Tevogen files periodic reports and current reports that detail its financial performance, operating strategy, and material events.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include audited or reviewed financial statements, management’s discussion and analysis, and commentary on Tevogen’s capital-efficient, cost-disciplined business model. For a company focused on precision T cell therapies and AI-enabled drug discovery, these filings provide context on research and development spending, general and administrative expenses, and non-GAAP measures such as adjusted loss from operations that Tevogen uses to describe operational performance.
Current reports on Form 8-K capture significant events, including listing and compliance matters. For example, Tevogen disclosed via Form 8-K that it received a Nasdaq notice regarding non-compliance with the $1.00 per share minimum bid price requirement, outlining the applicable compliance period and potential paths to regain compliance. Such filings help investors understand listing status and associated timelines.
The filings page also offers access to information related to equity structure, warrants, and other securities, as well as any proxy materials and, where applicable, insider transaction reports on Form 4. Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify items such as changes in operating loss, capital structure, or risk disclosures. Real-time updates from EDGAR ensure that new TVGN filings, from 10-Qs to 8-Ks, appear promptly with accessible explanations for investors analyzing Tevogen’s financial and regulatory trajectory.
Tevogen Bio Holdings Inc. presents its annual report as a clinical-stage immunotherapy company developing off-the-shelf CD8+ T cell therapies using its ExacTcell technology. Lead candidate TVGN 489 targets COVID‑19 and Long COVID in high‑risk and immunocompromised patients.
A Phase 1 proof‑of‑concept trial in ambulatory high‑risk adults reported no dose‑limiting toxicities, rapid viral load reductions, preserved patients’ own immunity, and no Long COVID over six months of follow‑up. Tevogen plans a pivotal trial in COVID‑19 patients with B‑cell malignancies and is exploring Long COVID treatment.
The pipeline extends to HPV‑related cancers, Epstein‑Barr virus in multiple sclerosis and lymphomas, and chronic hepatitis B, supported by the Tevogen.AI initiative for AI‑driven target discovery. The company highlights significant risks, including no approved products, reliance on substantial additional financing (including $7.0 million of grant funding), complex regulation, manufacturing build‑out, competition, and potential Nasdaq listing and stock price volatility.
Tevogen Bio Holdings Inc. filed a prospectus supplement dated March 25, 2026 that attaches a Form 8-K reporting the company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5450(a)(1).
The Nasdaq notice followed the implementation of a 1-for-50 reverse stock split that became effective on March 6, 2026. The supplement references the Prospectus dated May 7, 2025 and shows closing prices on March 24, 2026 of $5.22 for Common Stock and $0.0346 for Warrants.
Tevogen Bio Holdings Inc. reports that it has regained compliance with the Nasdaq minimum bid price requirement for continued listing on the Nasdaq Global Market. Nasdaq confirmed this status in a written notice dated March 20, 2026, and the matter is described as closed.
The company regained compliance after implementing a 1-for-50 reverse stock split of its common stock, which became effective on March 6, 2026. Tevogen’s common stock and warrants continue to trade on Nasdaq under the symbols TVGN and TVGNW.
Tevogen Bio Holdings Inc. officer Neal Flomenberg reported selling a total of 972 shares of common stock in three open-market transactions on March 10, 11, and 13, 2026. The shares were sold at weighted average prices of about $7.75, $7.26, and $6.40, with actual trades in ranges from $7.25–$7.33 and $6.39–$6.74.
According to the filing, these sales were made solely to satisfy tax obligations arising from the vesting and settlement of restricted stock units and were not made at Flomenberg’s discretion. After these transactions, he directly holds 76,940 shares of Tevogen Bio common stock.
Tevogen Bio Holdings Inc. effected a 1-for-50 reverse stock split of its common stock, effective March 6, 2026. The Company reported 202,416,556 shares issued and outstanding as of March 3, 2026 that will be combined at the 1-for-50 ratio.
The Common Stock will trade on Nasdaq on a split-adjusted basis under the same symbol, and the Company issued a new CUSIP, 88165K200. Fractional shares will not be issued; holders entitled to fractional shares will receive cash in lieu based on the closing trading price on the trading day immediately preceding the Effective Date. Convertible preferred shares, warrants and equity awards will be adjusted by dividing share counts by 50 and multiplying per-share conversion/exercise prices by 50.
Tevogen Bio Holdings Inc. is implementing a 1-for-50 reverse stock split of its common stock, effective March 6, 2026. The move is intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market.
As of March 3, 2026, the company had 202,416,556 shares of common stock issued and outstanding, which will be consolidated at the 50-to-1 ratio. Authorized common shares will remain at 800,000,000. No fractional shares will be issued; instead, holders entitled to a fraction will receive cash based on the closing price before the split.
The common stock will begin trading on a split-adjusted basis on March 6, 2026 under the same symbol, TVGN, with a new CUSIP number 88165K200. Outstanding preferred stock, warrants, equity awards, and plan share reserves will be adjusted proportionally, and the reverse split is designed to affect all stockholders uniformly, aside from minor changes from fractional share cash-out.
Tevogen Bio Holdings Inc. updated its prospectus supplement to report stockholder approvals from a February 19, 2026 special meeting. Shareholders approved an amendment adding 100,000,000 shares to the 2024 Omnibus Incentive Plan and approved a reverse stock split between 1:25 and 1:85, with the exact ratio and timing to be determined by the Board in its sole discretion.
The filing states there were 201,522,282 shares of Common Stock issued and outstanding as of January 21, 2026. Vote tallies show strong support for both proposals; the Plan Amendment received 147,777,455 votes for and the Reverse Stock Split Proposal received 176,344,447 votes for.
Tevogen Bio Holdings Inc. reported that stockholders approved two key proposals at a special meeting. First, they approved an amendment to the 2024 Omnibus Incentive Plan, adding 100,000,000 shares of common stock available for equity awards, which can be adjusted if a future reverse stock split occurs.
Stockholders also approved an amendment to the Certificate of Incorporation authorizing a reverse stock split of issued and outstanding common shares at a ratio between 1:25 and 1:85, with the exact ratio and timing left to the Board’s discretion, if implemented. At the record date, 201,522,282 shares were outstanding, and 182,412,517 shares were represented at the meeting. Both proposals received strong support based on the reported vote tallies.
Tevogen Bio Holdings Inc. insider plans to sell common stock under Rule 144. A holder has filed to sell 330,000 shares of Tevogen Bio common stock through Fidelity Brokerage Services LLC on or around 02/06/2026 on the NASDAQ, with an aggregate market value of $103,224.00.
The shares come from gifts received on 12/12/2025 (230,000 shares from Ryan Saad) and 12/16/2025 (100,000 shares from Kirt Desai). The filing also notes a prior sale of 15,500 Tevogen Bio shares for $5,116.55 on 12/31/2025 by Shrimad Rachandra Love & Care.
Tevogen Bio Holdings Inc. reported that its Board of Directors has expressed an intention to evaluate the potential declaration of a one-time special cash dividend for shareholders. Any dividend would follow the satisfaction of financial milestones that will be determined at a future date.
The update was shared through a press release issued on January 30, 2026 and furnished under a Regulation FD disclosure, signaling an early-stage, exploratory step rather than a finalized dividend decision.